Cobio’s platform is designed to support same‑shift diagnostic insight for bacterial infections, enabling earlier targeted therapy and improved patient management in hospital and reference laboratory settings.

By providing rapid, phenotypic susceptibility data, Cobio supports responsible antibiotic use, helping clinicians move away from prolonged empirical broad‑spectrum therapy.

The platform’s adaptability enables rapid incorporation of emerging or high‑priority bacterial threats, supporting surveillance and outbreak response efforts.

Cobio’s modular workflows, scalable instrumentation requirements, and AI‑assisted interpretation support deployment in resource‑limited environments where rapid phenotypic diagnostics are critically needed.

• Fieldable Combat Casualty Care

• Biothreat surveillance and Early Detection

• Decentralized minimally resourced clinics

Cobio is advancing a flexible diagnostic platform through federally supported research and translational development programs.

Current R&D efforts focus on:

• Expanding pathogen and antibiotic coverage

• Integrating multiple downstream detection technologies

• Refining AI‑enabled interpretation tools

• Validating performance using clinically relevant specimen types

Development priorities are informed by experimental data, industry insight, and feedback from practicing clinicians.